LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

Search

AbbVie Inc

Closed

SectorHealthcare

185.44 -1.29

Overview

Share price change

24h

Current

Min

181.55

Max

187.91

Key metrics

By Trading Economics

Income

-1.6B

3M

Sales

-1.8B

13B

P/E

Sector Avg

84.816

54.379

EPS

2.46

Dividend yield

3.31

Profit margin

0.02

Employees

55,000

EBITDA

3.2B

3.7B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+15.2% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.31%

2.55%

Next Earnings

24 Jul 2025

Next Dividend date

15 May 2025

Next Ex Dividend date

14 Jul 2025

Market Stats

By TradingEconomics

Market Cap

7.8B

351B

Previous open

186.73

Previous close

185.44

News Sentiment

By Acuity

24%

76%

59 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

AbbVie Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Apr 2025, 13:57 UTC

Earnings

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 Apr 2025, 12:52 UTC

Earnings

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 Apr 2025, 18:18 UTC

Major Market Movers

Pharma Shares Reverse Losses After Tariff Pause

9 Apr 2025, 09:39 UTC

Major Market Movers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27 Feb 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 Feb 2025, 13:41 UTC

Major Market Movers

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

7 May 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 Apr 2025, 12:44 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 Apr 2025, 09:33 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 Apr 2025, 16:03 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 Apr 2025, 14:00 UTC

Top News
Earnings

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 Apr 2025, 12:24 UTC

Top News
Earnings

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 Apr 2025, 12:03 UTC

Top News
Earnings

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Net $1.29B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q EPS 72c >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Adj EPS $2.46 >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Rev $13.34B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 Mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 Mar 2025, 15:04 UTC

Acquisitions, Mergers, Takeovers

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 Feb 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 Feb 2025, 13:25 UTC

Top News
Earnings

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 Feb 2025, 12:00 UTC

Earnings

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 Feb 2025, 12:00 UTC

Top News

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 Jan 2025, 15:50 UTC

Top News
Earnings

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

15.2% upside

12 Months Forecast

Average 215.6 USD  15.2%

High 250 USD

Low 194 USD

Based on 18 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

14

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

180.37 / 195.54Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

59 / 382 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.